Jones Financial Companies’s VistaGen Therapeutics VTGN Stock Holding History

Jones Financial Companies’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65	Hold	114	–	–	﹤0.01%	4660
2025 Q4	$75	Hold	114	–	–	﹤0.01%	4326
2025 Q3	$402	Hold	114	–	–	﹤0.01%	4060
2025 Q2	$225	Buy	114 +34	+43%	+$77	﹤0.01%	3905
2025 Q1	$207	Sell	80 -200	-71%	-$566	﹤0.01%	3592
2024 Q4	$826	Buy	280 +200	+250%	+$563	﹤0.01%	3164
2024 Q3	$246	Hold	80	–	–	﹤0.01%	2932
2024 Q2	$278	Hold	80	–	–	﹤0.01%	2373
2024 Q1	$422	Hold	80	–	–	﹤0.01%	1340
2023 Q4	$411	Buy	+80	New	+$303	﹤0.01%	996

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jones Financial Companies's VTGN Position: Q1 2026 in Review

Jones Financial Companies held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 114 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #4660.

Jones Financial Companies first reported a position in VTGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $826 in Q4 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Jones Financial Companies held 114 shares of VistaGen Therapeutics worth $65 as of Q1 2026.
Jones Financial Companies left its VistaGen Therapeutics share count unchanged in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4660 holding.
Jones Financial Companies first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 10 quarters since.
Jones Financial Companies's VistaGen Therapeutics position peaked at $826 in Q4 2024.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.